Close Menu
    Facebook X (Twitter) Instagram
    SciTechDaily
    • Biology
    • Chemistry
    • Earth
    • Health
    • Physics
    • Science
    • Space
    • Technology
    Facebook X (Twitter) Pinterest YouTube RSS
    SciTechDaily
    Home»Health»A Major Review Reveals Three Antidepressants That May Outperform Prozac
    Health

    A Major Review Reveals Three Antidepressants That May Outperform Prozac

    By The ConversationNovember 21, 2026No Comments5 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn WhatsApp Email Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email Reddit
    Various Medicine Pills Capsules Comparing Antidepressants
    A major new review suggests that some of the world’s most widely used antidepressants may be better than others at keeping depression symptoms under control over time. Credit: Shutterstock

    A massive review of 30,000 people suggests three antidepressants may outperform Prozac, but the findings reveal how much remains unknown about long-term depression treatment.

    A new review has found that some antidepressants may be more effective than others at helping people reduce the severity of their symptoms of depression over the long term.

    The research, published in The Lancet Psychiatry, found that people taking escitalopram (commonly sold as Lexapro), duloxetine (Cymbalta), and agomelatine (Valdoxan) were more likely to report improved symptoms over the long term than those taking fluoxetine (Prozac). For those taking Lexapro and Cymbalta, they were also more likely to stay on their medications.

    But does that mean these are the best antidepressants?

    Why do people take antidepressants long term?

    Around one in seven Australians will experience depression during their lifetime.

    Treatment can involve psychological therapies, social support and lifestyle changes, such as doing more exercise. For some people, these approaches may be enough to support recovery. For others, adding an antidepressant can be an important part of treatment.

    In 2024-2025, 3.8 million Australians were dispensed a prescription for an antidepressant.

    For adults with depression, clinical guidelines recommend continuing antidepressants for at least six months, and preferably 12 months, after an acceptable response to treatment is achieved.

    If, after six to 12 months, the depressive episode has resolved, it may be appropriate to reduce, and eventually stop the antidepressant. But symptoms can occur when discontinuing antidepressants, so it’s important this is done gradually, in consultation with a doctor.

    Studies of real-world antidepressant prescribing patterns in Australia suggest many people take antidepressants for longer than this. One 2022 study found nearly a quarter of those prescribed antidepressants were still receiving prescriptions for them two years later.

    Another Australian study found people take antidepressants for an average of four years.

    What did the researchers find?

    The new review set out to compare how well different antidepressants help people maintain improvements in depression. The researchers also compared how acceptable the medicines were to the people taking them. They measured this by looking at the proportion of people who stopped treatment for any reason during the study period.

    The researchers identified and reviewed 115 randomized controlled trials, involving more than 30,000 people. The researchers classified long-term use as six months or more. Their main analysis combined the results of 35 trials that directly compared one antidepressant with another.

    They found that three antidepressants – escitalopram, duloxetine and agomelatine – were associated with a greater likelihood of sustained response than fluoxetine.

    People taking escitalopram or duloxetine were also less likely to drop out of the trials than those taking fluoxetine.

    How reliable are the findings?

    The findings are interesting as escitalopram (Lexapro) is the most commonly prescribed antidepressant in Australia. It ranked number 13 out of all PBS-dispensed prescriptions in 2024–25. Duloxetine was number 45, but agomelatine isn’t available on the PBS.

    The findings suggest some antidepressants may be more effective than others at sustaining a response to treatment, but the results are far from definitive. More than half of the studies included in the main analysis were assessed as having a high risk of bias.

    This means some of the differences between antidepressants may reflect limitations in the original studies rather than genuine differences between the medicines. Some medicines were also supported by very few studies, making comparisons less certain.

    Another aspect to keep in mind when considering these results is what is meant by “long term.” The trials directly comparing antidepressants typically followed participants for around six months after they first started taking the medication. Only six studies followed participants for longer than six months.

    This means we still know relatively little about how the effectiveness of different antidepressants compares over longer periods. This is important given the average time people take them is much longer.

    What this research can’t tell us

    Importantly, these findings reflect average outcomes across groups of people. They can’t tell us which antidepressant will work best for any particular person.

    People respond differently to antidepressants, and what makes a medicine acceptable to one person may not be acceptable to another. While the researchers used trial drop-out rates as a measure of acceptability, this doesn’t necessarily capture people’s experiences of taking these medicines.

    For someone taking an antidepressant, acceptability might not be so binary. It may involve a trade-off between how the medication improves symptoms, its side effects, and how the medicine affects their everyday life.

    Continuing to take an antidepressant doesn’t necessarily mean someone finds it acceptable. Some people experience withdrawal symptoms when trying to stop, which can make discontinuation difficult.

    What’s the best fit for you?

    Ultimately, determining if an antidepressant is right for you, and which is the best fit, depends on many factors. These include your symptoms, other health conditions, previous experiences with medicines, potential side effects, and what matters most to you.

    If you’re taking an antidepressant that’s working well for you, the findings of this study aren’t a reason to switch.

    And if you’re considering starting, changing, or stopping an antidepressant, discuss your options with your doctor.

    Written by:

    • Jack Janetzki, Lecturer in Pharmacy and Pharmacology, Adelaide University
    • Lauren Cortis, Senior Lecturer in Pharmacy Practice, Adelaide University

    Adapted from an article originally published in The Conversation.The Conversation

    Never miss a breakthrough: Join the SciTechDaily newsletter.
    Follow us on Google and Google News.

    Depression Pharmaceuticals The Conversation
    Share. Facebook Twitter Pinterest LinkedIn Email Reddit

    Related Articles

    The FDA Approved a New Drug To Treat Alzheimer’s, but Medicare Won’t Always Pay for It – A Doctor Explains Biogen’s Aduhelm

    Improving Symptoms in Patients With Treatment-Resistant Depression Using Pharmacogenetics

    Depressed COVID Patients Respond Much Better Than Expected to SSRI Antidepressants

    Researchers Warn: Common Antidepressant Should No Longer Be Used To Treat People With Dementia

    Ivermectin Is a Game-Changing Nobel Prize-Winning Wonder Drug – But Not for COVID-19

    New Clues to Why Psychiatric Drugs Help Some, but Not Others

    Genes and Corresponding Proteins Discovered That May Lead to New Depression Treatments

    LSD May Offer Viable Treatment for Anxiety and Other Mental Disorders

    Antidepressant Fluvoxamine May Prevent Serious Illness in COVID-19 Patients

    Leave A Reply Cancel Reply

    • Facebook
    • Twitter
    • Pinterest
    • YouTube

    Don't Miss a Discovery

    Subscribe for the Latest in Science & Tech!

    Trending News

    Stanford Scientists Discover 3 Hidden Brain Types in Children With ADHD and Anxiety

    What Is a Thought Made Of? Scientists Reveal Why Human Consciousness May Be Beyond the Reach of AI

    Scientists Discover Mysterious Toxic Chemicals Floating in the Air Above America

    Astronomers Discover a Chilling Preview of Our Solar System’s Future

    Scientists Discover Alarming Signs of Extinction Risk Deep Beneath the Ocean

    A Common Gut Antibody May Be the Key to Preventing Colon Cancer Before It Starts

    Scientists Discover a Disturbing Link Between Cannabis Use and Earlier Psychosis

    Scientists Discover Two Monster Black Holes at the Dawn of Time That Shouldn’t Exist

    Follow SciTechDaily
    • Facebook
    • Twitter
    • YouTube
    • Pinterest
    • Newsletter
    • RSS
    SciTech News
    • Biology News
    • Chemistry News
    • Earth News
    • Health News
    • Physics News
    • Science News
    • Space News
    • Technology News
    Recent Posts
    • A Major Review Reveals Three Antidepressants That May Outperform Prozac
    • New Once-Daily Pill Slashes Bad Cholesterol by Nearly 65% in Clinical Trial
    • An Overlooked Property of Light Could Open the Door to a New Era of Optical Computing
    • NASA Smashed Into an Asteroid. Now ESA’s Hera Spacecraft Is About to Reveal the Damage
    • Does the Sun Have a Secret Companion? A Controversial Theory Could Explain Earth’s Mass Extinctions
    Copyright © 1998 - 2026 SciTechDaily. All Rights Reserved.
    • Science News
    • About
    • Contact
    • Editorial Board
    • Privacy Policy
    • Terms of Use

    Type above and press Enter to search. Press Esc to cancel.